HTG Molecular Diagnostics to Host Key Opinion Leader Meeting on Breast Cancer Molecular Diagnostics on October 29
TUCSON, Ariz., Oct. 22, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a diagnostic company whose mission is to advance precision medicine, today announced that it will host a Key Opinion Leader (KOL) luncheon at 12:00 pm ET on Tuesday, October 29th in New York City.
The event will feature a presentation by Adam Brufsky, M.D., Ph.D., Co-Director, Comprehensive Breast Cancer Center and Medical Director, Woman’s Cancer Center at the UPMC Magee Women’s Hospital, Pittsburgh PA, who will discuss the current challenges in diagnosing breast cancer and unmet medical needs and optimizing treatment. Dr. Brufsky will be available to answer questions at the conclusion of the event.
HTG Molecular Diagnostics' management team will provide an update of their development plan to build a comprehensive breast cancer diagnostic platform. This plan will showcase the product roadmap and milestones demonstrating the company’s progresses towards assays that can help clinicians improve the care of cancer patients.
Adam M. Brufsky, M.D., Ph.D., is Professor of Medicine at the University of Pittsburgh School of Medicine. He serves as Co-Director, Comprehensive Breast Cancer Center and Medical Director, Women’s Cancer Center at the UPMC Magee Women’s Hospital, Pittsburgh, PA. He also serves as the Associate Division Chief for the Division of Hematology/Oncology within the University of Pittsburgh School of Medicine’s Department of Medicine. Dr. Brufsky received a degree in Chemistry (Cum Laude) from Dartmouth College in Hanover, New Hampshire. He earned his M.D. and his Ph.D. in Developmental Biology at the University of Connecticut School of Medicine in Farmington, CT. He was an Intern and Resident in Internal Medicine at Brigham and Women’s Hospital, Harvard Medical School, Boston, MA. He then completed a Fellowship in Medical Oncology and Bone Marrow Transplantation and the Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, where his appointments included Associate Physician and Instructor in Medicine at Dana-Farber Cancer Institute and Harvard Medical School in Boston, MA. Dr. Brufsky is board certified in Internal Medicine and Medical Oncology by the American Board of Internal Medicine. He is an active member of the American Society of Clinical Oncology and the American Association for Cancer Research. He has authored or co-authored numerous abstracts and research articles in leading journals, including the New England Journal of Medicine, Journal of Clinical Investigation, Journal of Clinical Oncology, and Lancet. Dr. Brufsky is Principal Investigator on a number of research grants funded by the National Institutes of Health, Susan G. Komen Foundation, and US Army Breast Cancer Research Program.
This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. Members of the media and the public are invited to participate via the live webcast.
About HTG:
HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. The company’s mission is to empower precision medicine.
Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Phone: (617) 430-7577
Email: arr@lifesciadvisors.com
